Additional Intraoperative Autologous-Derived Platelet-Rich Stroma to Transanal Flap Repair for the Treatment of Cryptoglandular Transsphincteric Fistulas in a Tertiary Referral Center: Long-Term Outcomes of a Prospective Pilot Study

Publication date

2025-02

Authors

Bak, Michiel T.J.
Witjes, Caroline D.M.
Dwarkasing, Roy S.
Arkenbosch, Jeanine H.C.
Schouten, W. Rudolph
van Veen, Jochem C.
van Dongen, Joris A
Fuhler, Gwenny M.
van der Woude, C. Janneke
de Vries, Annemarie C.

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Transanal advancement flap repair (TAFR) fails in approximately 30–40% of patients with a cryptoglandular transsphincteric fistula. An additional intraoperative injection of autologous platelet-rich stroma (PRS) with TAFR proved to be safe, feasible, and effective in the short term for the treatment of cryptoglandular transsphincteric fistula in a tertiary referral center. In this study, we assessed the long-term outcomes in patients with a cryptoglandular transsphincteric fistula who were treated with an additional intraoperative autologous PRS injection with TAFR (n = 43). The majority of the patients (88%) had a complex transsphincteric fistula (high transsphincteric and/or multiple side tracts) and underwent (one or more) fistula procedure(s) aimed at fistula repair (56%) before study inclusion. At a median follow-up time of 4.2 years [IQR 3.5–5.1], long-term primary clinical closure (i.e., clinical closure of the treated external fistula opening(s) after TAFR with additional PRS injection without the need for any re-interventions during long-term follow-up) was observed in 77% of the patients. Subsequently, 94% of these patients also reached radiological healing (i.e., fibrotic fistula tract on MRI). Recurrence after clinical closure or radiological healing was observed in 9% and 5%. Unplanned re-interventions were performed in 12% of the patients for recurrent or residual fistulizing disease. In this uncontrolled pilot study, additional autologous PRS injection with TAFR showed promising outcomes, as long-term primary clinical closure and, subsequently, radiological healing was reached in the vast majority of tertiary referral patients with a (complex) cryptoglandular transsphincteric fistula at long-term follow-up. In addition, recurrence rates were low. Future randomized research is warranted to study the effects of PRS.

Keywords

autologous, cell therapy, perianal fistula, platelet-rich plasma, platelet-rich stroma, stromal vascular fraction, Bioengineering

Citation

Bak, M T J, Witjes, C D M, Dwarkasing, R S, Arkenbosch, J H C, Schouten, W R, van Veen, J C, van Dongen, J A, Fuhler, G M, van der Woude, C J, de Vries, A C & van Ruler, O 2025, 'Additional Intraoperative Autologous-Derived Platelet-Rich Stroma to Transanal Flap Repair for the Treatment of Cryptoglandular Transsphincteric Fistulas in a Tertiary Referral Center : Long-Term Outcomes of a Prospective Pilot Study', Bioengineering, vol. 12, no. 2, 105. https://doi.org/10.3390/bioengineering12020105